| A TYK2 inhibitor being developed by Bristol Myers Squibb for the treatment of multiple immune-mediated diseases, including psoriasis (e.g. plaque psoriasis), psoriatic arthritis, lupus and inflammatory bowel disease |
| Received its first approval on 9 September 2022 in the USA |
| Approved for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.